Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools
Authors:
- Osama SolimanOSOsama Soliman
- On behalf of the Precision Cardio-Oncology Enterprise (P-CORE) InvestigatorsOIOn behalf of the Precision Cardio-Oncology Enterprise (P-CORE) Investigators
- 29 September 2021
- journal article
- letter
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 190 (3) , 355-356
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancerBreast Cancer Research and Treatment, 2021
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathyProceedings of the National Academy of Sciences, 2002